Pappas Capital

Pappas Capital is a long-running investment management firm based in Research Triangle Park, North Carolina, with a focus on precision life science products, medical technologies, and therapeutics. The portfolio includes Aktis Oncology, a precision-oncology platform — a useful signal that the firm engages with science-driven therapeutic platforms and not just commercial-stage devices. AI is not the headline thesis; the firm’s edge is its life sciences pedigree and proximity to the RTP biotech and academic ecosystem.

The fund invests at Series A and Series B with check sizes between $5M and $25M, making it a candidate for lead or substantial co-investor positions in mid-stage life sciences rounds. The North Carolina base reflects deep ties to the RTP cluster, though Pappas deploys nationally rather than regionally.

Founders should approach Pappas Capital when they are building a precision therapeutic, a life sciences tool with a clear scientific differentiator, or a device with strong clinical underpinnings. Early discovery without a credible lead asset, services models, and pure healthtech software are not the right fit. Because the firm covers three sub-verticals — life sciences tools, devices, and therapeutics — founders should target the pitch to the relevant area and partner. Expect rigorous scientific diligence, an interest in IP and platform extensibility, and a partner that thinks about clinical milestones and partnering options. Bring a sharp value-inflection roadmap and a clean IP narrative.